Analyst Research

Report Title Price
Provider: irasia.com
$81.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Benitec Biopharma Ltd announces positive lung cancer preclinical results


Tuesday, 17 Dec 2013 05:42pm EST 

Benitec Biopharma Ltd:Says the results of pre-clinical experiments confirming the ability to significantly increase survival in non-small cell lung cancer (NSCLC) in vivo.Says Tribetarna (a ddRNAi‚Äźbased therapeutic) provides significantly increased survival in a preclinical in vivo model of lung cancer.Says After six weeks 78 pct. of animals dosed with a combination of Tribetarna and cisplatin lived, compared with only 20 pct. of the animals in the control groups.Says the study confirms previously reported results that silencing the gene target of Tribetarna, beta III tubulin, overcomes the resistance of NSCLC tumours to chemotherapy.Says preliminary submission filed with the US FDA. 

Company Quote

0.735
0.06 +8.89%
21 Nov 2014